-- 
Cellectis Advances 6% After Getting $68.8 Million Investment

-- B y   P h i l   S e r a f i n o
-- 
2011-09-15T07:56:31Z

-- http://www.bloomberg.com/news/2011-09-15/cellectis-advances-6-after-getting-68-8-million-investment.html
  Cellectis (ALCLS)  SA, a French
pharmaceutical company that works on stem cells, rose as much as
6 percent in Paris trading after getting a 50-million-euro
($68.8 million) investment and agreeing to buy a Swedish
company.  Cellectis rose 28 cents, or 5 percent, to 5.93 euros at
9:45 a.m.  France â€™s Strategic Investment Fund will invest 25
million euros, while Pierre Bastid, a private investor, will
invest 25 million euros, the Romainville, France-based company
said in a statement today.  Cellectis will buy Cellartis, a Swedish company that also
works on stem cells, for 18.3 million euros, according to the
statement.  To contact the editor responsible for this story:
Phil Serafino at 
 pserafino@bloomberg.net  